Please: Login/Register

The Latest Edition of "Eyes on malaria" magazine will be out very soon!! | CALL FOR ARTICLES: AMMREN is inviting journalists / writers / scientists interested in reporting on malaria to send articles for publication in its international magazine “Eyes on Malaria” and for posting on its website. Please contact the AMMREN Secretariat for more details click here. Enjoy your stay!. Volunteers and interns urgently needed to work with an NGO working in the area of malaria and health. Apply through - ammren1@gmail.com / ammren1@yahoo.com. Journalists interested in reporting on and writing articles on health issues should please reply through this email: ammren1@gmail.com

ANNOUNCEMENTS:::

TIPS ON MALARIA

  • HOW CAN MOSQUITOES BE CONTROLLED?

    Mosquitoes around the home can be reduced significantly by minimizing the amount of standing water available for mosquito breeding. Residents are urged to reduce standing water around the home in a variety of ways.

  • HOW CAN I PROTECT MYSELF FROM MOSQUITO-BORN DISEASES?

    The best way is to avoid being bitten by mosquitoes.This can be accomplished using personal protecting  while outdoors when mosquitoes are present. Treated bed nets should be used sleeping. Mosquito repellent should be used when outdoor.

  • WHO ARE AT RISK?


    Nearly half of the world’s population is at risk of getting malaria. Pregnant women are particularly at risk of malaria. Children under 5 years are at high risk of malaria.
     

MAGAZINE EDITIONS

  • First Edition

  • Second Edition

  • Third Edition

  • Fourth Edition

  • Fifth Edition

  • Sixth Edition

  • Seventh Edition

  • Eighth Edition

  • Ninth Edition

  • Special Edition

  • INESS Edition

  • Tenth Edition

  • INDEPTH Edition

  • Eleventh Edition

  • Twelfth Edition

  • Special Edition

  • Special Edition

  • Volume 1

  • Volume 2

SANARIA'S PFSPZ-CVAC VACCINE ACHIEVES HIGH LEVEL PROTECTION AGAINST MALARIA IN CLINICAL TRIAL

 
In a report published in Nature, vaccine investigators from University of Tübingen reported all nine subjects (100%) immunized with three doses of Sanaria PfSPZ-CVac malaria vaccine were protected against Plasmodium falciparum malaria when exposed to the disease 10 weeks after last vaccine dose.
 
Sanaria CEO, Stephen L. Hoffman, said clinical trials of PfSPZ-CVac underway or soon to start in Germany, the U.S., Equatorial Guinea, Mali, Gabon, and Ghana will lead to an optimized vaccination regimen.
 
“We expect to move rapidly into phase 3 clinical trials and licensure. Our goal is to use PfSPZ-CVac in mass vaccination programs to eliminate the malaria parasite and to prevent malaria in travelers.”
 
 PfSPZ-CVac is composed of live, purified malaria parasites and an antimalarial drug.
Volunteers in the clinical trial received three 0.5mL injections of the vaccine by rapid direct venous inoculation. There was no difference in adverse events between volunteers who received the vaccine and those who received the saltwater placebo.
 
The German Center for Infection Research funded the current trial with additional support from Sanaria, which receives support from multiple other institutions in the U.S., Europe, and Africa that participate in the International PfSPZ Consortium.
 
African children are hardest hit by malaria. In 2015 malaria caused 214M clinical episodes and 438,000 deaths worldwide according to WHO. This devastating impact occurs despite investment of billions of dollars in malaria control efforts. Malaria is also a concern for tourists, diplomats, business travelers, aid workers, industrial workers, and military personnel worldwide.
 
Professor Ogobara Doumbo, MD, PhD, Director of the Bamako Malaria Research Training Center (Mali), said “those of us in countries where people's lives are devastated by malaria have been waiting for a highly effective malaria vaccine for decades. We are excited about these results with PfSPZ-CVac, and are proud to be able to initiate the first field trials of PfSPZ-based vaccines in Mali, West Africa.”
 
Professor of Tropical Medicine and Travel Medicine, Martin Grobusch MD, PhD, Director of the Center of Tropical medicine at the University of Amsterdam's Academic Medical Center said “travelers continue to be at high risk of acquiring malaria. A vaccine like PfSPZ-CVac that provides complete protective immunity for 10 weeks and can be administered in less than two weeks will be an ideal tool for the prevention of malaria in the traveling population.”
 
In a report published in Nature, vaccine investigators from University of Tübingen reported all nine subjects (100%) immunized with three doses of Sanaria PfSPZ-CVac malaria vaccine were protected against Plasmodium falciparum malaria when exposed to the disease 10 weeks after last vaccine dose.
 
Sanaria CEO, Stephen L. Hoffman, said clinical trials of PfSPZ-CVac underway or soon to start in Germany, the U.S., Equatorial Guinea, Mali, Gabon, and Ghana will lead to an optimized vaccination regimen.
 
“We expect to move rapidly into phase 3 clinical trials and licensure. Our goal is to use PfSPZ-CVac in mass vaccination programs to eliminate the malaria parasite and to prevent malaria in travelers.”
 
Credit: Sanaria Inc.